Pharmaceutical Executive Daily: Peptide Ruling Stalls
From Pharmaceutical Executive · · 2 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.